RxDoctor Payments Data

Ara Kayayan, MD

Internal Medicine · Albany, NYNPI 1205828316

Payments from drug & device makers

$10,853in general payments, 2019–2025

Across 641 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • GSK$978
  • Pfizer$667
  • Boehringer Ingelheim$584
  • Lilly USA, LLC$555
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$10,842100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,853 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$73,201
Medicare patients
278
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$171,037
OzempicSemaglutide117$131,291
TrulicityDulaglutide30$47,014
XifaxanRifaximin15$43,281
JanuviaSitagliptin Phosphate41$41,342
MounjaroTirzepatide39$40,052
JardianceEmpagliflozin49$37,273
MyrbetriqMirabegron53$33,842
TradjentaLinagliptin32$27,262
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$25,691
FarxigaDapagliflozin Propanediol34$24,715
LyricaPregabalin21$22,877
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$15,254
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$13,658
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$9,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$667$193,913183 claims
Novo NordiskOzempic$1,061$131,291117 claims
Lilly USA, LLCTrulicity, Mounjaro$555$87,06669 claims
Boehringer IngelheimJardiance, Tradjenta$584$64,53581 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$353$43,28115 claims
MerckJanuvia$217$41,34241 claims
AstraZenecaFarxiga, Breztri Aerosphere$451$38,37345 claims
GSKTrelegy Ellipta, Anoro Ellipta$978$34,91046 claims
Astellas Pharma US IncMyrbetriq$234$33,84253 claims
AbbVieSynthroid$2,064$4,32850 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$142$3,601268 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →